SMMT: Summit Therapeutics Inc. Quarterly EPS earnings growth

Public company logo of Summit Therapeutics (SMMT)

The market value of Summit Therapeutics (SMMT) previously surged due to positive results from Phase 3 Ivonescimab trials. Quarterly EPS variability reflects current profit dynamics, with the metric standing at 16.50. Growth prospects rely on synergy with Asian antibody laboratories and classic scaling through the patenting of low-cost production molecules for global distribution.

Summit Therapeutics plc (SMMT) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/13/2026

Summary analytical data breakdowns for Summit Pharma (SMMT)

- share price and expert price forecast:
Stock Price Summit Therapeutics Inc.|SMMT - Forecast Levels Chart
- market capitalization information:
Market Capitalization Summit Therapeutics Inc|SMMT - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Summit Therapeutics|SMMT - Company Net Assets|Market Cap to Net Assets Ratio summittxinc.com|SMMT - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Summit Therapeutics|SMMT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Summit Therapeutics|SMMT - Company Cumulative Debt|Debt to Book Capitalization Ratio Summit Therapeutics Inc|SMMT - Company Long-Term Indebtedness|Company Short-Term Debt Summit Therapeutics|Quick Liquidity summittxinc.com
- earnings and valuation multiples indicators:
SMMT - Net Financial Result|Future Profit Summit Therapeutics|SMMT - P/E Multiple|Future Price to Earnings Summit Therapeutics Inc|SMMT - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Summit Therapeutics Inc|SMMT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Summit Therapeutics|SMMT - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months summittxinc.com|SMMT - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Summit Therapeutics
Comprehensive company analysis:Summit Therapeutics
Flagship merchandise of Summit Therapeutics

Summit Therapeutics minimizes scientific risks through the development of oncology and antibiotic drugs. The dynamics of these processes are reflected in the quarterly growth of earnings per share. This metric captures daily changes in the growth rates of net profit per share. It demonstrates the efficiency of scaling the business into actual revenue during upturns. Ignoring the cyclicality of peak values may lead to a capital overvaluation when the trend shifts.

Key competitors

MRNA: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months PCVX (Vaxcyte Inc)|TARS (Tarsus Pharma) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CorMedix Therapeutics CRMD|Quarterly EPS earnings growth MCRB|Year-over-year net earnings per share growth for the last 12 months sperotherapeutics.com SPRO|SCYNEXIS - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months ANTX (AN2 Therapeutics Inc)|PolyPid Limited - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months YS Biopharma Co., Ltd. LSB|iterumtx.com (ITRM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix Inc|Year-over-year earnings per share growth for the last 12 months SXTP (60 Degrees Pharma)|Year-over-year earnings per share growth for the last twelve months Oragenics, Inc. (OGEN)|Year-over-year net earnings per share change for the last twelve months OpGen Corporation